MiniMed Group, Inc.

MiniMed Group is among the leading diabetes device manufacturers identified by Seagrove Partners and has the largest global footprint in its industry, operating in approximately 80 countries and serving more than 640,000 insulin pump users as of October 2025. According to Seagrove Partners’ November 2025 market model, Insulet, Tandem, Ypsomed, and Beta Bionics—companies MiniMed Group considers its closest insulin pump competitors—operate in 16, 23, 16, and one country, respectively.

MiniMed Group advances its mission through a well-invested, global, and experienced workforce of approximately 8,000 dedicated employees worldwide, including more than 3,000 commercial employees, supported by two world-class dedicated manufacturing facilities. Commercially and operationally, its scaled global infrastructure represents a significant barrier to entry, reflecting decades of operating experience outside the United States. Since 2001, MiniMed Group has produced more than five million insulin pumps. The company has extensive experience navigating diverse local regulatory and reimbursement frameworks and has made the substantial upfront investments required to establish a presence across its markets. In going to market, MiniMed Group promotes education in AID, expands access to its products in the United States across distribution channels and health plans, and differentiates itself outside the United States through participation in national tender regimes.